BioNTech Investor Day Presentation Deck

1 Neoantigen prediction How do we identify, predict, and characterize neoantigens? a CD4+ T cells CD4+ T cell Mutated DNA DC Activation CD8+ T cell MOOMOO Recognition of cancer-associated mutations by cytotoxic T cells¹ Tumor-draining lymph node Tumor Biology relevant for immunogenicity Tumour cell Mutated peptide/ neo-epitope Uptake Cross presentation CTL b Stability Amount Neo-epitope # HLA-I TCR Tumor CD8+ T cell Localization Expression Clonality Processing MHC binding/stability TCR binding Tolerance Biology relevant for tumor cell recognition ● ● ● ● ● Digital & AI/ML Type of the mutation (SNV, INDEL, Fusion..)2 Clonality of the mutation (clonal, subclonal) 3,4 Mutation position (anchor, non-anchor, TCR accessibility) 5-7 Mutated transcript expression level8,⁹ Similarity to foreign antigens/lack of self-similarity² Peptide/HLA binding strength (affinity, off-rate)² 1 Türeci Ö, et al. Nat Biomed Eng 2018; 2:566-569; 2 Sahin U. AACR Annual Meeting 2022; Oral presentation; 3 McGranahan N, et al. Science 2016; 351:1463-1469; 4 Gejman RS, et al. eLife 2018; 7:e41090; 5 Duan F, et al. J Exp Med 2014; 211:2231-2248; 6 Balachandran VP, et al. Nature 2017; 551:512-516; 7 Yadav M, et al. Nature 2014; 515:572-576; 8 Kreiter S, et al. Nature 2015; 520:692-696; 9 Abelin JG, et al. Immunity 2017; 46:315-326. BIONTECH 39

View entire presentation